[1]
S. Changsatja, C. . Kositamongkol, L. . Thamlikitkul, P. . Phisalprapa, and T. . Komonpaisarn, “COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN RESECTED EGFR-MUTATED EARLY-STAGE NON-SMALL CELL LUNG CANCER IN THAILAND”, ICOPH, vol. 9, no. 1, pp. 45–67, Jan. 2025.